4559 Zeria Pharmaceutical
- 2325
- +33+1.44%
Zeria Pharmaceutical News
Zeria Pharmaceutical's Attributable Profit Climbs 12% in Fiscal H1
Zeria Pharmaceutical: Confirmation letter
Zeria Pharmaceutical: Half-Year Report - Term 71 (2024/04/01 - 2025/03/31)
JFE revises down to 160 billion yen from 260 billion yen for the third quarter.
JFE <5411> announced a revision to the financial estimates for the fiscal year ending March 2025. The sales revenue was revised downward from 5 trillion 240 billion yen to 4 trillion 970 billion yen, and the operating profit was revised downward from 260 billion yen to 160 billion yen. In the iron & steel business, due to the rise in construction costs in the domestic building materials sector and labor shortages, further demand deceleration is expected, as well as stagnation in demand for Asia-bound steel for automobiles, resulting in a standalone crude steel production volume of around 22.4 million tons, which is 0.6 million tons lower than the previous outlook. [Positive Rating] <9001>
Zeria Pharmaceutical Reports Strong Mid-Year Growth
Zeria Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
Toyota, Itochu, NYK Line, Nitori Holdings (6th)
※The above calendar is only a schedule and may be subject to change depending on the company's circumstances.---------------------------------------November 6th (Wed) <1301> Kyokuyo <1332> Nissui <1420> Sanyo H <165A> SBI Leos <1799> Daiichi Construction <1814> Oomatsu Ken <1884> Nichi Doro <1898> Seiki Tokyu <196
Zeria Pharmaceutical: Notice regarding revisions to earnings forecasts
Line Yahoo, Mitsubishi Heavy, nintendo co ltd, Kawasaki ship (5th)
※The above calendar is just a schedule and may be subject to change depending on the company's convenience.---------------------------------------November 5th (Tuesday)＜1723＞Nihondenki＜1787＞Nakabotech＜1826＞Satakensha＜1945＞Tokyo Enesis＜1967＞Yamato＜2222＞Kotobuki Spirits＜2281＞Prima Ham＜2372＞Ayro inc
Zeria Pharmaceutical To Go Ex-Dividend On September 27th, 2024 With 23 JPY Dividend Per Share
September 26th (Japan Standard Time) - $Zeria Pharmaceutical(4559.JP)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 30th, 2024 will receive 23 JPY dividend per
Veltassa (Patiromer) Approved in Japan for the Treatment of Adults With Hyperkalemia
List of stocks with cleared skies (weekly chart) (Part 1)
○ Cloud escapement stock list market Code Stock name Closing price Leading span A Leading span B Tokyo Stock Exchange Main Board < 1873> Nippon House HD 340 316.75 338.5< 1899> Fukuda Group 5500 5402.5 5115< 2220> Kameda Koji 4355 4348.75 4287.5< 2269> Meiji H
Zeria Pharmaceutical's Attributable Profit Soars 45% in Fiscal Q1
Zeria Pharmaceutical's Attributable Profit Jumps 45% in Fiscal Q1
List of stocks with cleared clouds (Part 2) [Ichimoku Kinko Hyo: List of Stocks with Cleared Clouds]
- List of stocks that broke through below the cloud Market Code Name Closing Price Leading Span A Leading Span B Tokyo Stock Exchange Prime ＜4099＞ Shikoku Chemicals 1731 2059.25 1899 ＜4188＞ Mitsubishi Chemicals 744 848 861.5 ＜4194＞ Visional 6780 7165 7410 ＜4272＞
List of cloud-clearing stocks (weekly) (part 2)
Below is a list of stocks that have broken through the clouds. Exchange Code, Stock Name, Closing Price, Leading Span A, Leading Span B Tokyo Stock Exchange Prime, <4507>, Shionogi & Co., Ltd., 6370, 6991.75, 6612.5 <4534>, Mochida Pharmaceutical Co., Ltd., 3215, 3296.25, 3445 <4551>, Torii Pharmaceutical Co., Ltd., 3450, 3662.5, 3500 <4559>
Investment strategy for today, August 2nd.
[Fisco Selected Stock] [Material Stock] Nitto Boseki <3110> 5610 yen (8/1) is engaged in businesses such as glass fiber, in vitro diagnostic pharmaceuticals, fibers, and beverages. It has upwardly revised its performance forecast for the fiscal year ending in March 2025, with an operating profit estimate of 15 billion yen (up 78.8% from the previous year). It raised the previous estimate by 20%. This is due to factors such as the first quarter operating profit of 3.907 billion yen (4.4 times the same period last year) and continued strong demand for AI servers contributing to earnings.
Identify the situation where the clear sense of hitting bottom is becoming stronger.
[Stock Opening Comment] The Japanese stock market on the 2nd is likely to be a movement to find the immediate bottom amid the continued significant decline. On the 1st, the US market saw the NY Dow down 494 points and the Nasdaq down 405 points. The sell-off strengthened on high alert for the economic downturn, as initial jobless claims reached a high level in a year and the ISM Manufacturing Activity Index unexpectedly decreased. The Chicago Nikkei 225 futures settlement price was 36,845 yen, down 1,105 yen from Osaka. The exchange rate of the yen is around 149.30 yen per dollar.
Pay attention to Konami Group and Nitto Boseki, while Yamato Holdings and Kyocera Corporation Sponsored ADR may be sluggish.
On the US stock market yesterday, the Dow Jones Industrial Average closed at 40,347.97, down 494.82 points, while the Nasdaq Composite Index closed at 17,194.14, down 405.26 points. The Chicago Nikkei 225 Futures closed at 36,845 yen, down 1105 yen from the Osaka market's closing price. The exchange rate was 1 dollar = 149.30-40 yen. In today's Tokyo market, Shin-Etsu Chemical Co., Ltd. <7224> reported an operating profit that was 2.8 times higher than the same period last year in the first quarter, Konami Holdings Corp. <9766> reported a 46.6% increase, and Zeria Pharmaceutical Co., Ltd. <4559> reported a 32.6% increase.
Nippon Steel revised its forecast upwards on March 25, with net profit increasing from 300 billion yen to 340 billion yen.
Nippon Steel <5401> announced a revision to its financial estimates for the 2025 fiscal year, with net profits being upwardly revised from 300 billion yen to 3,400 billion yen. Although the steel demand slump continues, the margin (spread) between raw material prices and steel sales prices is improving. In the first quarter of the 2025 fiscal year, sales revenue was 2.191509 trillion yen, down 0.4% from the same period last year, and operating profit was 236.977 billion yen, down 4.7% from the same period last year, surpassing the consensus estimate of about 175 billion yen. 【Plus
Analysis
Price Target
No Data
No Data